Welcome to our dedicated page for Intuitive Surgical SEC filings (Ticker: ISRG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Intuitive Surgical, Inc. (ISRG) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed issuer headquartered in Sunnyvale, California, Intuitive uses these filings to report financial results, material events, and other information relevant to shareholders and regulators.
Among the key documents available are current reports on Form 8-K. Recent 8-K filings include items reporting quarterly financial results under Item 2.02, where Intuitive furnishes press releases detailing revenue, procedure growth on its da Vinci surgical systems and Ion endoluminal system, and changes in the installed base of systems. Another 8-K filing reports a change in the role of a senior executive under Item 5.02, illustrating how the company discloses updates related to its leadership structure.
Investors also use Intuitive’s SEC filings to follow information that may appear in annual reports on Form 10-K and quarterly reports on Form 10-Q, such as risk factor discussions, descriptions of the company’s business and technologies, and summaries of regulatory and market conditions affecting robotic-assisted surgery and minimally invasive care. While these specific forms are not reproduced in the provided excerpts, they are part of the broader filing set accessible through the SEC’s EDGAR system.
On Stock Titan, ISRG filings are paired with AI-powered summaries designed to explain the content and context of complex documents. These tools can help readers understand the significance of earnings releases, regulatory updates, or governance changes without reading every line of each filing. Users can also review filings that relate to financial reporting, such as exhibits containing press releases, and monitor how Intuitive communicates procedure trends, system placements, and other operational metrics to the market.
For investors researching Intuitive’s regulatory history, this page serves as a focused entry point to the company’s SEC disclosures, including 8-Ks that reference earnings announcements and other material developments.
Curet McAdams filed a notice of proposed sale under Rule 144 to sell 421 shares of the issuer’s common stock, with an aggregate market value of $208,378.16, through Morgan Stanley Smith Barney LLC on or around 02/11/2026 on NASDAQ.
The 421 common shares were acquired from the issuer on 02/10/2026 as restricted stock, with the same date shown as the payment date and the consideration marked as not applicable. In the prior three months, McAdams also completed several smaller common stock sales with disclosed gross proceeds.
Intuitive Surgical CEO David J. Rosa reported routine stock-based compensation activity. On February 10, 2026, 1,436 restricted stock units from a February 10, 2023 grant vested and converted into the same number of common shares at an exercise price of $0.0.
A portion of these shares, 724 common shares at $492.84 per share, was withheld to cover statutory tax obligations. After these transactions, Rosa directly holds 229,570 shares of Intuitive Surgical common stock. The RSUs vest in four equal annual installments of 25%, contingent on continued service.
Intuitive Surgical director Gary S. Guthart reported the vesting and settlement of 2,633 restricted stock units (RSUs) into an equal number of common shares on February 10, 2026. The RSUs vest 25% per year over four years starting February 10, 2023.
To cover statutory tax withholding on this vesting, 1,306 common shares were withheld at a value of $492.84 per share, leaving 5,021 common shares held directly after the transactions. In addition, Guthart has indirect beneficial ownership of common stock through trusts for a daughter, a son, and another trust.
An insider associated with ISRG has filed notice of intent to sell 105 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $51,938.25. The approximate sale date listed is 02/10/2026.
The filing notes that these 105 shares were acquired on 02/10/2026 via a stock option exercise paid in cash. The issuer’s common shares outstanding are shown as 355,130,237. Over the past three months, the same seller has reported several prior sales, including 230 shares on 01/27/2026 for gross proceeds of $122,500.30.
Intuitive Surgical executive Gary Loeb, EVP & Chief Legal and Compliance, reported routine equity activity. On February 10, 2026, 315 restricted stock units vested and were converted into common stock on a one-for-one basis. A portion of the newly issued shares was withheld at a price of $492.84 per share to satisfy statutory tax obligations. After these transactions, Loeb beneficially owned 3,704 shares of common stock directly and 314 restricted stock units that remain subject to future vesting.
Intuitive Surgical (ISRG) senior vice president Iman Jeddi reported routine equity vesting and tax withholding transactions. On February 10, 2026, 838 restricted stock units granted on February 10, 2023 converted into 838 shares of common stock at an exercise price of $0.0.
A portion of these shares—309—was automatically withheld at a value of $492.84 per share to cover statutory taxes, leaving 585 shares held directly after the transactions. In addition, 26,649 shares of Intuitive Surgical common stock are reported as held indirectly by a trust associated with the reporting person. The RSU award vests 25% annually over four years, with each vested RSU converting into one share of common stock.
Intuitive Surgical EVP & CFO Jamie Samath reported routine equity compensation activity. On February 10, 2026, 1,077 restricted stock units (RSUs) converted into 1,077 shares of common stock at an exercise price of $0.0, increasing his directly held shares to 8,295 before tax withholding.
On the same date, 496 common shares were withheld at $492.84 per share to cover statutory taxes, leaving 7,799 common shares owned directly afterward. The RSUs vest 25% per year over four years starting on each anniversary of February 10, 2023, with each RSU delivering one share of common stock when it vests, subject to continued service.
Intuitive Surgical EVP Henry L. Charlton reported routine equity compensation activity. On February 10, 2026, 1,077 restricted stock units (RSUs) vested and converted into common shares at $0.0 per share. To cover statutory taxes, 492 shares were surrendered at $492.84 per share, leaving 3,697 common shares held directly and 1,077 RSUs outstanding. The RSU award vests in 25% annual installments on each anniversary of February 10, 2023, contingent on continued service.
Intuitive Surgical executive Mark Brosius reported routine equity compensation activity. On February 10, 2026, 838 restricted stock units granted on February 28, 2023 converted into the same number of common shares at an exercise price of $0.00.
To cover statutory tax withholding, 433 common shares were automatically disposed of at $492.84 per share, leaving Brosius with 592 shares of Intuitive Surgical common stock held directly after the transactions. The RSUs vest in four equal annual installments, each representing 25% of the award.
Intuitive Surgical senior executive Iman Jeddi filed an initial statement of ownership, detailing equity awards and indirect common stock holdings. As of January 29, 2026, a trust associated with Jeddi held 26,649 shares of Intuitive Surgical common stock. Jeddi also directly holds several non-qualified stock options and stock units. These include options to buy 5,625, 3,760, 5,028, 3,760 and 5,028 shares of common stock at exercise prices ranging from $76.9989 to $304.67 per share, with expirations between August 2026 and August 2030. The filing further lists performance stock units of 2,702 and 5,585 shares for which performance criteria have been achieved, vesting in 2027 and 2026, and multiple restricted stock unit grants totaling several thousand shares that vest over a four-year schedule.